Iza-bren

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerBreast NeoplasmsUrothelial Cancer

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

12

Anktiva

SSWOG Cancer Research Network

Phase 3

13

Carboplatin/paclitaxel

AstraZeneca

Phase 3

34

Iza-bren

Bristol-Myers Squibb

Phase 3

35

Remeron

OOrganon and Co

Preclinical

16

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—7

Treatment

GSK

Preclinical

18

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

110

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Recruiting·Bristol-Myers Squibb·Preclinical·NCT07100080·500 enrolled

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

Not yet recruiting·Bristol-Myers Squibb·Phase 3·NCT07680790·850 enrolled

Combination Of Izalontamab Brengitecan And Adagrasib In Advanced KRAS G12Ci-Refractory Non-Small Cell Lung Cancer - The IZA-A Trial

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07382726·18 enrolled

Breast Neoplasms1 trial

IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

Recruiting·Bristol-Myers Squibb·Preclinical·NCT06926868·600 enrolled

Urothelial Cancer1 trial

IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment

Recruiting·Bristol-Myers Squibb·Preclinical·NCT07106762·470 enrolled

Details

Drug Info

Related News